Ascension Asset Management LLC Sells 1,100 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Ascension Asset Management LLC decreased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 9.1% during the 3rd quarter, Holdings Channel.com reports. The firm owned 10,988 shares of the medical research company’s stock after selling 1,100 shares during the period. Thermo Fisher Scientific accounts for about 3.0% of Ascension Asset Management LLC’s investment portfolio, making the stock its 4th largest holding. Ascension Asset Management LLC’s holdings in Thermo Fisher Scientific were worth $3,200,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the company. Nuveen Asset Management LLC boosted its holdings in Thermo Fisher Scientific by 10,824.0% in the second quarter. Nuveen Asset Management LLC now owns 1,928,966 shares of the medical research company’s stock valued at $566,498,000 after acquiring an additional 1,911,308 shares during the last quarter. Jennison Associates LLC boosted its holdings in Thermo Fisher Scientific by 2,589.9% in the second quarter. Jennison Associates LLC now owns 819,138 shares of the medical research company’s stock valued at $240,564,000 after acquiring an additional 788,686 shares during the last quarter. Putnam Investments LLC boosted its holdings in Thermo Fisher Scientific by 2,645.9% in the second quarter. Putnam Investments LLC now owns 720,795 shares of the medical research company’s stock valued at $211,683,000 after acquiring an additional 694,545 shares during the last quarter. AQR Capital Management LLC boosted its holdings in Thermo Fisher Scientific by 38.8% in the second quarter. AQR Capital Management LLC now owns 2,141,471 shares of the medical research company’s stock valued at $621,561,000 after acquiring an additional 598,230 shares during the last quarter. Finally, Janus Henderson Group PLC boosted its holdings in Thermo Fisher Scientific by 22.9% in the second quarter. Janus Henderson Group PLC now owns 2,986,916 shares of the medical research company’s stock valued at $877,186,000 after acquiring an additional 555,802 shares during the last quarter. Institutional investors and hedge funds own 88.21% of the company’s stock.

NYSE:TMO opened at $280.99 on Wednesday. The business’s 50-day moving average is $288.36 and its two-hundred day moving average is $281.45. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.49 and a quick ratio of 1.07. Thermo Fisher Scientific Inc. has a 12 month low of $208.34 and a 12 month high of $305.45. The firm has a market capitalization of $112.70 billion, a PE ratio of 25.27, a price-to-earnings-growth ratio of 1.84 and a beta of 1.13.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, July 24th. The medical research company reported $3.04 EPS for the quarter, beating the consensus estimate of $3.01 by $0.03. Thermo Fisher Scientific had a return on equity of 17.11% and a net margin of 14.24%. The company had revenue of $6.32 billion for the quarter, compared to analyst estimates of $6.31 billion. During the same period last year, the company posted $2.75 earnings per share. The firm’s revenue was up 3.9% compared to the same quarter last year. Equities analysts anticipate that Thermo Fisher Scientific Inc. will post 12.25 EPS for the current year.

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 50,000 shares of the firm’s stock in a transaction dated Tuesday, July 30th. The stock was sold at an average price of $284.83, for a total value of $14,241,500.00. Following the transaction, the chief executive officer now directly owns 342,193 shares of the company’s stock, valued at $97,466,832.19. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jim P. Manzi sold 1,833 shares of the firm’s stock in a transaction dated Thursday, August 15th. The shares were sold at an average price of $272.93, for a total value of $500,280.69. Following the completion of the transaction, the director now directly owns 28,592 shares in the company, valued at $7,803,614.56. The disclosure for this sale can be found here. Insiders sold 54,104 shares of company stock worth $15,418,539 over the last three months. 0.45% of the stock is currently owned by corporate insiders.

A number of brokerages recently weighed in on TMO. Needham & Company LLC lifted their target price on Thermo Fisher Scientific from $315.00 to $321.00 and gave the company a “buy” rating in a report on Thursday, July 25th. Credit Suisse Group reiterated a “buy” rating and issued a $310.00 target price on shares of Thermo Fisher Scientific in a report on Wednesday, July 31st. ValuEngine cut Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd. Finally, Barclays set a $330.00 target price on Thermo Fisher Scientific and gave the company a “buy” rating in a report on Monday, July 15th. One investment analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Thermo Fisher Scientific presently has an average rating of “Buy” and a consensus price target of $305.27.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

See Also: Buy-Side Analysts

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.